◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Shanghai Haohai Biological Technology Co., Ltd. (6826) Financial History

Name: Shanghai Haohai Biological Technology Co., Ltd. (6826) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-10-02

Shanghai Haohai Biological Technology Co., Ltd. (6826) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 1,999 employees. Its market capitalization is roughly HK$4 billion. In the fiscal year ended 2025-12-31, 6826 reported CNY 2.4B in revenue and CNY 251M in net income.

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally.

Interactive charts & full statements → Open the 6826 valuation workbench →

6826 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 2.4B	CNY 2.7B	CNY 2.6B	CNY 2.1B
Gross Profit	CNY 1.7B	CNY 1.9B	CNY 1.9B	CNY 1.4B
Operating Income (EBIT)	CNY 317M	CNY 446M	CNY 438M	CNY 220M
Net Income	CNY 251M	CNY 420M	CNY 416M	CNY 180M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6826 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 229M)	(CNY 260M)	(CNY 68M)	(CNY 122M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6826 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 6.7B	CNY 7.1B	CNY 7.1B	CNY 6.9B	—
Total Liabilities	CNY 1.1B	CNY 1.2B	CNY 1.1B	CNY 990M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6826 viewer.

Other Companies in Biotechnology

3378 · Hanx Biopharmaceuticals (Wuhan) Co., Ltd. — HK$4 billion
CPRX · Catalyst Pharmaceuticals Inc — $4 billion
2509 · Qyuns Therapeutics Co., Ltd. — HK$4 billion
2629 · Mirxes Holding Company Limited — HK$4 billion
GPCR · Structure Therapeutics Inc. — $3 billion
LYKALABS · Lyka Labs Limited — ₹3 billion
2197 · Clover Biopharmaceuticals, Ltd. — HK$3 billion
BION · BB Biotech AG — CHF 3 billion

← 6824 All “0-9” companies 6828 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.